Company intelligence / Profile preview
Syntis Bio
Boston, Massachusetts, United Statessyntis.bio ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
SYNT-101 has shown promising results in preclinical rodent models with consistent 1% weekly weight loss over a six-week period while preserving 100% of lean muscle mass. In a first-in-human pilot study, an investigational formulation demonstrated evidence of nutrient redirection and satiety hormone modulation with strong safety and tolerability[7].
- Therapeutic areas
- Metabolic DisordersEndocrinologyGastroenterology
- Modalities
- Oral therapiesengineered enzymespolymer-based drug delivery
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Codexis, Inc. (acquired enzyme portfolio from them in April 2024)
Beyond the preview
Go deeper on Syntis Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syntis Bio.